Parsaclisib
INCB 50465-203 (CITADEL-203)
Phase 2 small_molecule completed
Quick answer
Parsaclisib for Lymphoma is a Phase 2 program (small_molecule) at Incyte with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Incyte
- Indication
- Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed